As of 2025-09-18, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -2.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 127.60 mil USD. SGMO's TTM EBITDA according to its financial statements is -62.02 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 15.9x | 14.9x |
| Forward P/E multiples | 19.2x - 40.6x | 29.9x |
| Fair Price | (3.82) - (3.14) | (4.48) |
| Upside | -794.5% - -671.1% | -914.1% |
| Date | EV/EBITDA |
| 2025-09-17 | -1.88 |
| 2025-09-16 | -1.88 |
| 2025-09-15 | -1.82 |
| 2025-09-12 | -1.84 |
| 2025-09-11 | -1.97 |
| 2025-09-10 | -1.97 |
| 2025-09-09 | -1.91 |
| 2025-09-08 | -1.94 |
| 2025-09-05 | -2.04 |
| 2025-09-04 | -1.96 |
| 2025-09-03 | -1.98 |
| 2025-09-02 | -2.01 |
| 2025-08-29 | -1.91 |
| 2025-08-28 | -2.02 |
| 2025-08-27 | -2.00 |
| 2025-08-26 | -2.01 |
| 2025-08-25 | -2.06 |
| 2025-08-22 | -2.23 |
| 2025-08-21 | -2.17 |
| 2025-08-20 | -2.01 |
| 2025-08-19 | -2.11 |
| 2025-08-18 | -2.25 |
| 2025-08-15 | -2.20 |
| 2025-08-14 | -2.01 |
| 2025-08-13 | -2.01 |
| 2025-08-12 | -1.90 |
| 2025-08-11 | -1.52 |
| 2025-08-08 | -1.60 |
| 2025-08-07 | -1.73 |
| 2025-08-06 | -1.96 |
| 2025-08-05 | -1.96 |
| 2025-08-04 | -1.98 |
| 2025-08-01 | -2.11 |
| 2025-07-31 | -1.99 |
| 2025-07-30 | -2.03 |
| 2025-07-29 | -2.15 |
| 2025-07-28 | -2.30 |
| 2025-07-25 | -2.23 |
| 2025-07-24 | -2.29 |
| 2025-07-23 | -2.04 |
| 2025-07-22 | -1.72 |
| 2025-07-21 | -1.79 |
| 2025-07-18 | -1.86 |
| 2025-07-17 | -1.73 |
| 2025-07-16 | -1.72 |
| 2025-07-15 | -1.72 |
| 2025-07-14 | -1.81 |
| 2025-07-11 | -1.78 |
| 2025-07-10 | -1.81 |
| 2025-07-09 | -1.94 |